{"id":"influenza-a-virus","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Nausea (antivirals)"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":{"setId":"ced9a8b6-ef2c-a620-c61c-ff9374249543","title":"FLUZONE TIV SH 2026 (INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), AND INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED)) INJECTION, SUSPENSION [SANOFI VACCINES US INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Influenza A Virus is the causative agent of seasonal and pandemic influenza. Merck's marketed products against this virus include inactivated influenza vaccines (e.g., Fluzone) that stimulate immune responses, and antivirals like oseltamivir (Tamiflu) that inhibit viral neuraminidase to prevent viral release from infected cells. These interventions either prevent infection or reduce viral replication and symptom severity.","oneSentence":"This is not a drug but a pathogenic virus; Merck manufactures vaccines and antivirals against Influenza A Virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:07:58.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza A infection"},{"name":"Treatment of acute influenza A infection"}]},"trialDetails":[{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT05332899","phase":"PHASE1","title":"Influenza Human Challenge Model","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-05-24","conditions":"Influenza","enrollment":80},{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT07215871","phase":"PHASE1","title":"Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza Infection, Infections, Respiratory Virus Infections","enrollment":33},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT04743609","phase":"NA","title":"RSV Burden in Outpatient and Hospital Settings","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2021-02-08","conditions":"RSV Infection, Children, Only, Outpatient","enrollment":1900},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT06479226","phase":"PHASE3","title":"Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2022-06-05","conditions":"Healthy","enrollment":150},{"nctId":"NCT07110532","phase":"PHASE1","title":"pH1N1 Blinded Challenge Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Influenza","enrollment":180},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT06753474","phase":"PHASE1","title":"A/Texas Flu Challenge","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-02-04","conditions":"Influenza","enrollment":50},{"nctId":"NCT04901455","phase":"EARLY_PHASE1","title":"Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-03","conditions":"COPD","enrollment":24},{"nctId":"NCT06863142","phase":"PHASE1","title":"Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-28","conditions":"Influenza Prevention, Seasonal Influenza","enrollment":45},{"nctId":"NCT05864118","phase":"NA","title":"Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2023-08-21","conditions":"Respiratory Tract Infections","enrollment":1000},{"nctId":"NCT07420985","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2025-10-24","conditions":"Influenza, Acute Respiratory Viral Infection","enrollment":300},{"nctId":"NCT05202379","phase":"PHASE1","title":"CC-42344 Safety Study in Healthy Participants","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2022-02-11","conditions":"Influenza A","enrollment":80},{"nctId":"NCT07403019","phase":"","title":"Burden of Respiratory Viruses in India.","status":"NOT_YET_RECRUITING","sponsor":"MAHAN Trust","startDate":"2026-04-01","conditions":"Pneumonia","enrollment":2000},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT07019883","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-06-12","conditions":"Avian Influenza","enrollment":80},{"nctId":"NCT07111078","phase":"PHASE1","title":"Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-27","conditions":"Influenza Prevention, Pandemic Influenza Prevention","enrollment":56},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT07349017","phase":"PHASE1","title":"A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-02-07","conditions":"Influenza","enrollment":160},{"nctId":"NCT07327398","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-07","conditions":"Influenza","enrollment":1200},{"nctId":"NCT07342556","phase":"NA","title":"Evaluating Modes of Influenza Transmission 2b Baseline SAR","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, College Park","startDate":"2026-01","conditions":"Influenza (Healthy Volunteers)","enrollment":80},{"nctId":"NCT07302256","phase":"PHASE1","title":"A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-16","conditions":"Influenza","enrollment":120},{"nctId":"NCT06024096","phase":"PHASE4","title":"Systems Biological Assessment of Statin Effect on Vaccine Responses","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-09-20","conditions":"Vaccine Response","enrollment":63},{"nctId":"NCT04682444","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.","status":"COMPLETED","sponsor":"Joint Stock Company \"Farmak\"","startDate":"2009-04-13","conditions":"Acute Respiratory Viral Infections, Human Influenza","enrollment":100},{"nctId":"NCT07308158","phase":"","title":"Covid Flu A/B and RSV 4 in 1 Diagnostic Test","status":"COMPLETED","sponsor":"iHealth Labs inc","startDate":"2024-11-15","conditions":"Influenza A, Influenza B, COVID - 19","enrollment":1119},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT05968989","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT06999603","phase":"PHASE2","title":"Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection","status":"RECRUITING","sponsor":"Synairgen Research Ltd.","startDate":"2025-09-02","conditions":"Viral Pneumonia","enrollment":550},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT05447078","phase":"PHASE3","title":"Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection","status":"COMPLETED","sponsor":"University of Mississippi Medical Center","startDate":"2022-07-01","conditions":"Healthy Volunteers","enrollment":492},{"nctId":"NCT07305207","phase":"PHASE1","title":"Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness","status":"NOT_YET_RECRUITING","sponsor":"Dalhousie University","startDate":"2026-02-01","conditions":"Influenza (Healthy Volunteers)","enrollment":32},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT05569239","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg","status":"ACTIVE_NOT_RECRUITING","sponsor":"Osivax","startDate":"2025-09-08","conditions":"Influenza","enrollment":2850},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT04515446","phase":"NA","title":"Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-02-04","conditions":"Flu","enrollment":18},{"nctId":"NCT07254052","phase":"","title":"Effectiveness of Ammonium Chloride in Reducing Viral Load","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-09-01","conditions":"RNA Virus Infections, Viral Infection COVID-19, Influenza A and B","enrollment":32},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT05979350","phase":"NA","title":"Metagenomic NGS for Diagnosis of Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-08-07","conditions":"Pneumonia, Diagnosis","enrollment":114},{"nctId":"NCT05624450","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-13","conditions":"Viral Lung Infection and Acute Respiratory Failure","enrollment":2870},{"nctId":"NCT07121192","phase":"PHASE2","title":"A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-25","conditions":"Influenza, Human","enrollment":776},{"nctId":"NCT07147517","phase":"","title":"Preparedness Through Respiratory Virus Epidemiology and Community Engagement","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-10-08","conditions":"Respiratory Infection Virus, COVID -19, RSV","enrollment":25000},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT07217639","phase":"NA","title":"Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings","status":"NOT_YET_RECRUITING","sponsor":"Aptitude Medical Systems","startDate":"2025-11-01","conditions":"COVID -19, Influenza A, Influenza B","enrollment":2000},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT06850298","phase":"NA","title":"H5N1 Milk Detection Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-05-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT06842173","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2025-09-01","conditions":"Avian Influenza A Virus","enrollment":700},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT07168759","phase":"NA","title":"Educational VR Game Intervention to Enhance Hygiene Practices in Primary School Children","status":"ENROLLING_BY_INVITATION","sponsor":"The Hong Kong Polytechnic University","startDate":"2023-05-02","conditions":"Healthy Participants","enrollment":2160},{"nctId":"NCT01063608","phase":"PHASE4","title":"Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza A Virus, H1N1 Subtype","enrollment":147},{"nctId":"NCT04978454","phase":"PHASE1","title":"Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":"Influenza","enrollment":60},{"nctId":"NCT05666245","phase":"NA","title":"DMID 21-0041; Influenza CVD 59000","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2023-02-20","conditions":"Influenza","enrollment":34},{"nctId":"NCT06613737","phase":"NA","title":"Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain","status":"COMPLETED","sponsor":"Hvivo","startDate":"2024-09-11","conditions":"Influenza A H3N2","enrollment":33},{"nctId":"NCT05975840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-03","conditions":"Influenza, Human","enrollment":518},{"nctId":"NCT02198638","phase":"NA","title":"Effect of Influenza Vaccination of Healthcare Workers (HCW) on the Risk of Influenza in Patients Hospitalized in Short Stays Units","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-12","conditions":"Patient With Influenza Like Illness","enrollment":541},{"nctId":"NCT06278324","phase":"NA","title":"Effectiveness of a Nasal Spray on Viral Respiratory Infections","status":"COMPLETED","sponsor":"CEN Biotech","startDate":"2024-01-26","conditions":"Acute Respiratory Tract Infection, Flu, Human, COVID-19","enrollment":76},{"nctId":"NCT06684379","phase":"PHASE1, PHASE2","title":"Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)","status":"RECRUITING","sponsor":"PEACHES BIOTECH","startDate":"2024-10-02","conditions":"SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections","enrollment":50},{"nctId":"NCT05818124","phase":"PHASE1","title":"Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-21","conditions":"Influenza Infection","enrollment":161},{"nctId":"NCT04960397","phase":"PHASE1","title":"Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-10","conditions":"H3N2 Influenza","enrollment":140},{"nctId":"NCT06060457","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-25","conditions":"Respiratory Syncytial Virus","enrollment":1900},{"nctId":"NCT05972174","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-07-10","conditions":"Influenza","enrollment":1504},{"nctId":"NCT07063849","phase":"PHASE1","title":"Pilot Influenza Challenge Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daniel Hoft, MD, PhD","startDate":"2025-05-20","conditions":"Influenza","enrollment":12},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT06097273","phase":"PHASE3","title":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-19","conditions":"SARS-CoV-2, Influenza","enrollment":8061},{"nctId":"NCT07041671","phase":"NA","title":"Evaluation Viral RNA and Virus Infectivity in Exhaled Air Before and After Use of One Dose With ColdZyme Mouth Spray","status":"NOT_YET_RECRUITING","sponsor":"Lund University","startDate":"2025-09-30","conditions":"URTI - Viral Upper Respiratory Tract Infection","enrollment":200},{"nctId":"NCT06008457","phase":"","title":"Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit","status":"COMPLETED","sponsor":"Sequenom, Inc.","startDate":"2023-04-17","conditions":"COVID-19 Respiratory Infection, Influenza A, Influenza Type B","enrollment":1600},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT06841913","phase":"PHASE4","title":"Woodsmoke Exposure, Influenza Infection, and Nasal Immunity","status":"SUSPENDED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-10-01","conditions":"Smoke Exposure, Influenza","enrollment":112},{"nctId":"NCT06972810","phase":"NA","title":"Human Infection Study of H3N2 Influenza in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2025-05-05","conditions":"Influenza","enrollment":12},{"nctId":"NCT06582277","phase":"PHASE2","title":"Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836","status":"COMPLETED","sponsor":"Osivax","startDate":"2024-10-22","conditions":"Vaccine-Preventable Diseases, Influenza","enrollment":117},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT04896853","phase":"PHASE1","title":"Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®","status":"ACTIVE_NOT_RECRUITING","sponsor":"NextCell Pharma Ab","startDate":"2021-05-18","conditions":"COVID-19 Acute Respiratory Distress Syndrome, Influenza A, Metapneumovirus Pneumonia","enrollment":9},{"nctId":"NCT06620185","phase":"NA","title":"GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2025-04-16","conditions":"Influenza","enrollment":36},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT00417560","phase":"NA","title":"Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2007-01","conditions":"Influenza","enrollment":""},{"nctId":"NCT05027932","phase":"PHASE1","title":"Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-06-27","conditions":"Influenza","enrollment":45},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT06247059","phase":"NA","title":"Reducing Respiratory Virus Transmission in Bangladeshi Classrooms","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-10","conditions":"SARS-CoV2 Infection, Influenza Viral Infections, Respiratory Viral Infection","enrollment":20000},{"nctId":"NCT06780566","phase":"NA","title":"Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection in the Emergency Department Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-04-30","conditions":"Influenza, COVID-19, Acute Respiratory Infections (ARIs)","enrollment":1050},{"nctId":"NCT06890429","phase":"PHASE2","title":"Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults","status":"COMPLETED","sponsor":"Research Institute of Influenza, Russia","startDate":"2023-12-07","conditions":"Respiratory Synctial Virus Infections","enrollment":120},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT05162547","phase":"","title":"Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay","status":"COMPLETED","sponsor":"QIAGEN Gaithersburg, Inc","startDate":"2022-03-11","conditions":"Respiratory Disease","enrollment":2383},{"nctId":"NCT05436444","phase":"PHASE1","title":"Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-23","conditions":"Influenza Infection","enrollment":35},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT06476275","phase":"PHASE1","title":"Single Dose Texas 2017 (H3N2) Challenge Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-11","conditions":"Influenza Viral Infections","enrollment":33},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT06342349","phase":"PHASE1","title":"A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-03-30","conditions":"Influenza","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16340,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Influenza A Virus","genericName":"Influenza A Virus","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"This is not a drug but a pathogenic virus; Merck manufactures vaccines and antivirals against Influenza A Virus. Used for Prevention of seasonal influenza A infection, Treatment of acute influenza A infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}